Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | LAP3 | P28838 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5707322 | 0.98 | CA2 (0.47) | CA2CA1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3990465 | 0.85 | CA1 (0.34) | CA2CA1 | |
| SCHEMBL27343088 | 0.83 | CA1 (0.45) | CA2CA1SLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL28191311 | 0.82 | CA1 (0.37) | CA2CA1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL12895596 | 0.81 | CA2 (0.58) | CA2CA1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL19895753 | 0.79 | CA2 (0.62) | CA2CA1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL500233 | 0.79 | CA2 (0.46) | CA2CA1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL20788560 | 0.77 | USP2 (0.38) | CA2CA1SLC1A3SLC1A2SLC1A1 | |
| Trifluoroacetic Acid SCHEMBL8367842 | 0.77 | CA2 (0.48) | CA2CA1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL27868293 | 0.77 | CA1 (0.30) | CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101454330-A | Hydroxylated amide skin moisturizer | OREAL (FR) | 2009-06-10 | — | — | CN | claimed |
| EP-2021345-A1 | HYDROXYLATED AMIDE SKIN MOISTURIZER | L'Oreal (FR) | 2009-02-11 | — | — | EP | claimed |
| WO-2007137925-A1 | HYDROXYLATED AMIDE SKIN MOISTURIZER | L'OREAL (FR) | 2007-12-06 | — | — | WO | claimed |
| WO-2024030651-A1 | GPX4 INHIBITORS AND USE THEREOF | SONATA THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2020-04-09 | — | — | US | disclosed |
| CN-106432311-A | Processes and intermediates for producing azaindoles | 沃泰克斯药物股份有限公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-106336413-A | Compounds used as JAK inhibitor, and use of compounds | 广东东阳光药业有限公司 | 2017-01-18 | — | — | CN | disclosed |
| EP-2763535-A1 | AZAINDOLES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013052355-A1 | AZAINDOLES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-04-11 | — | — | WO | disclosed |
| EP-2021345-A1 | HYDROXYLATED AMIDE SKIN MOISTURIZER | L'Oreal (FR) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007137925-A1 | HYDROXYLATED AMIDE SKIN MOISTURIZER | L'OREAL (FR) | 2007-12-06 | — | — | WO | disclosed |
| CN-1046524-C | Cephalosporin derivatives | HOFFMANN LA ROCHE (CH) | 1999-11-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | CA2 3741/4885CA1 3778/4885SLC1A3 147/4885 |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | CA2 3741/4885CA1 3778/4885SLC1A3 147/4885 |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | CA2 4386/4885CA1 4552/4885SLC1A3 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.